

David Rizzieri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11224374/publications.pdf>

Version: 2024-02-01

24
papers

1,618
citations

516710

16
h-index

610901

24
g-index

24
all docs

24
docs citations

24
times ranked

3014
citing authors

#	ARTICLE	IF	CITATIONS
1	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
2	Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 669.e1-669.e8.	1.2	4
3	Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Cancer Investigation</i> , 2021, 39, 871-879.	1.3	6
4	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18
5	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	5.2	89
6	Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 515-522.	2.3	10
7	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
8	Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. <i>Cancer</i> , 2018, 124, 325-334.	4.1	57
9	Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 679-686.	0.4	3
10	A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 434-441.	2.5	86
11	Guadecitabine (SGI-110) in treatment-naïve patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1317-1326.	10.7	148
12	Zevalin® (ibrutinomab tiuxetan): After more than a decade of treatment experience, what have we learned?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 105, 5-17.	4.4	78
13	CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia. <i>Cancer Cell</i> , 2016, 30, 792-805.	16.8	86
14	Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia. <i>Cell Stem Cell</i> , 2015, 17, 152-164.	11.1	58
15	Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 1252-1257.	1.6	57
16	Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 1099-1110.	10.7	249
17	A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. <i>Leukemia and Lymphoma</i> , 2014, 55, 2114-2119.	1.3	11
18	Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia. <i>Nature Genetics</i> , 2014, 46, 245-252.	21.4	97

#	ARTICLE	IF	CITATIONS
19	Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. <i>Lancet Oncology</i> , The, 2012, 13, 696-706.	10.7	109
20	Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2492-2499.	1.6	165
21	Elacytarabine, a novel 5- β -elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia. <i>Leukemia Research</i> , 2012, 36, e71-e73.	0.8	13
22	Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. <i>Leukemia and Lymphoma</i> , 2008, 49, 543-553.	1.3	138
23	High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 666-673.	2.0	4
24	Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 274-278.	2.0	26